Skip to main content

Advertisement

Table 2 Relative risks of HHF and ESRD in SU group vs. DPP4i group (2nd cohort)

From: Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study

Study outcomes Total History of baseline HF No history of baseline HF
SU + MET (n = 4674) DPP4i + MET (n = 9348) P-value SU + MET (n = 412) DPP4i + MET (n = 824) P-value SU + MET (n = 4262) DPP4i + MET (n = 8524) P-value
HHF
 N. of events 70 131   44 73   26 58  
 Cumulative incidence at 3 years (%)a 1.70 (1.30–2.23) 2.20 (1.82–2.67)   11.08 (8.00–15.26) 13.40 (10.53–16.97)   0.73 (0.47–1.15) 1.09 (0.81–1.47)  
 HR (95% CI) at 3 yearsb 1.00 1.39 (1.02–1.90) 0.0369 1.00 1.29 (0.86–1.95) 0.2250 1.00 1.61 (0.97–2.67) 0.0634
 Cumulative incidence at 5 years (%)a 2.97 (2.25–3.91) 3.30 (2.46–4.44)   19.96 (14.24–27.58) 19.44 (12.38–29.79)   1.21 (0.77–1.91) 1.68 (1.15–2.45)  
 HR (95% CI) at 5 yearsb 1.00 1.26 (0.95–1.67) 0.1132 1.00 1.12 (0.77–1.64) 0.5574 1.00 1.51 (0.96–2.39) 0.0765
  1. All of cardiovascular and renal outcomes were assessed using a Cox proportional hazards models comparing dipeptidyl-peptidase 4 inhibitor with sulfonylurea in combination with metformin after propensity score matching (PMS). PSM was performed by an optimal 2:1 (case: control) matching within a radius of 0.01
  2. HF, heart failure; DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitor; HHF, hospitalization for heart failure; N, number; HR, hazard ratio; CI confidence interval; and ESRD, end-stage renal disease
  3. aCumulative incidence was calculated based on Kaplan–Meier estimation
  4. bP-value by cox proportional regression model for clustered data
  5. cAdjusted for creatinine
Study outcomes Total History of baseline HF No history of baseline HF
SU + MET (n = 4066) DPP4i + MET (n = 7635) P-value SU + MET (n = 333) DPP4i + MET (n = 613 P SU + MET (n = 3733) DPP4i + MET (n = 7022) P-value
ESRD eventsc
 N. of events 11 17   2 4   9 13  
 Cumulative incidence at 3 years (%)a 0.34 (0.16–0.73) 0.42 (0.25–0.70)   0.00 1.23 (0.43–3.51)   0.37 (0.17–0.81) 0.35 (0.20–0.63)  
 HR (95% CI) at 3 yearsb 1.00 1.55 (0.65–3.71) 0.3255    1.00 1.17 (0.47–2.92) 0.7298
 Cumulative incidence at 5 years (%)a 0.77 (0.38–1.54) 0.48 (0.29–0.80)   1.81 (0.45–7.11) 1.23 (043–3.51)   0.67 (0.31–1.48) 0.42 (0.23–0.75)  
 HR (95% CI) at 5 yearsb 1.00 1.10 (0.54–2.28) 0.7905 1.00 1.81 (0.45–7.11) 0.3977 1.00 1.04 (0.46–2.35) 0.9313
  1. All of cardiovascular and renal outcomes were assessed using a Cox proportional hazards models comparing dipeptidyl-peptidase 4 inhibitor with sulfonylurea in combination with metformin after propensity score matching (PMS). PSM was performed by an optimal 2:1 (case: control) matching within a radius of 0.01
  2. HF, heart failure; DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitor; HHF, hospitalization for heart failure; N, number; HR, hazard ratio; CI confidence interval; and ESRD, end-stage renal disease
  3. aCumulative incidence was calculated based on Kaplan–Meier estimation
  4. bP-value by cox proportional regression model for clustered data
  5. cAdjusted for creatinine